Capital Bank & Trust Co Buys 25,135 Shares of Grifols SA, Barcelona (GRFS)

Capital Bank & Trust Co increased its holdings in shares of Grifols SA, Barcelona (NASDAQ:GRFS) by 7.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 375,361 shares of the biotechnology company’s stock after purchasing an additional 25,135 shares during the period. Capital Bank & Trust Co owned approximately 0.05% of Grifols SA, Barcelona worth $8,217,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Comerica Bank lifted its holdings in shares of Grifols SA, Barcelona by 1.3% in the second quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 245 shares in the last quarter. Advisor Group Inc. lifted its holdings in shares of Grifols SA, Barcelona by 2.8% in the second quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 309 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Grifols SA, Barcelona by 0.7% during the second quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock valued at $1,004,000 after acquiring an additional 327 shares during the last quarter. Bank of Montreal Can increased its position in shares of Grifols SA, Barcelona by 0.7% during the second quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock valued at $1,480,000 after acquiring an additional 457 shares during the last quarter. Finally, Wetherby Asset Management Inc. increased its position in shares of Grifols SA, Barcelona by 3.0% during the second quarter. Wetherby Asset Management Inc. now owns 18,731 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 544 shares during the last quarter. 22.50% of the stock is owned by institutional investors and hedge funds.

Grifols SA, Barcelona (NASDAQ GRFS) traded up $0.48 during trading hours on Tuesday, reaching $23.40. The company had a trading volume of 970,314 shares, compared to its average volume of 643,050. The company has a quick ratio of 1.39, a current ratio of 3.17 and a debt-to-equity ratio of 1.69. Grifols SA, Barcelona has a 12 month low of $15.90 and a 12 month high of $24.20. The company has a market capitalization of $15,650.30, a price-to-earnings ratio of 25.16, a price-to-earnings-growth ratio of 1.72 and a beta of 1.05.

GRFS has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Citigroup started coverage on Grifols SA, Barcelona in a research report on Tuesday, October 31st. They issued a “buy” rating for the company. UBS Group downgraded Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. Finally, BidaskClub cut Grifols SA, Barcelona from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $24.00.

TRADEMARK VIOLATION NOTICE: “Capital Bank & Trust Co Buys 25,135 Shares of Grifols SA, Barcelona (GRFS)” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.truebluetribune.com/2018/01/03/capital-bank-trust-co-has-8-22-million-holdings-in-grifols-sa-barcelona-grfs.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply